Evrofarma Valuation
| EVROF Stock | EUR 3.64 0.24 6.19% |
At this time, the firm appears to be overvalued. Evrofarma SA shows a prevailing Real Value of €3.41 per share. The current price of the firm is €3.64. Our model computes the value of Evrofarma SA from reviewing the firm fundamentals such as Current Valuation of 33.15 M, profit margin of (0.03) %, and Shares Outstanding of 13.67 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Evrofarma's price fluctuation is moderately volatile at this time. Calculation of the real value of Evrofarma SA is based on 3 months time horizon. Increasing Evrofarma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Evrofarma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Evrofarma Stock. However, Evrofarma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.64 | Real 3.41 | Hype 3.64 | Naive 3.98 |
The real value of Evrofarma Stock, also known as its intrinsic value, is the underlying worth of Evrofarma SA Company, which is reflected in its stock price. It is based on Evrofarma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Evrofarma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Evrofarma SA helps investors to forecast how Evrofarma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evrofarma more accurately as focusing exclusively on Evrofarma's fundamentals will not take into account other important factors: Evrofarma Total Value Analysis
Evrofarma SA is currently forecasted to have takeover price of 33.15 M with market capitalization of 11.49 M, debt of 18.45 M, and cash on hands of 554 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Evrofarma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
33.15 M | 11.49 M | 18.45 M | 554 K |
Evrofarma Investor Information
About 76.0% of the company shares are held by company insiders. The company last dividend was issued on the 18th of July 2008. Evrofarma SA had 2:1 split on the 26th of July 2001. Based on the key measurements obtained from Evrofarma's financial statements, Evrofarma SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Evrofarma Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Evrofarma suggests not a very effective usage of assets in December.Evrofarma Ownership Allocation
Evrofarma SA retains a total of 13.67 Million outstanding shares. Evrofarma SA shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 76.0 percent of Evrofarma SA outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.Evrofarma Profitability Analysis
The company reported the revenue of 38.81 M. Net Loss for the year was (355 K) with profit before overhead, payroll, taxes, and interest of 3.84 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Evrofarma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Evrofarma and how it compares across the competition.
About Evrofarma Valuation
The stock valuation mechanism determines Evrofarma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Evrofarma. We calculate exposure to Evrofarma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evrofarma's related companies.8 Steps to conduct Evrofarma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Evrofarma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Evrofarma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Evrofarma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Evrofarma's revenue streams: Identify Evrofarma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Evrofarma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Evrofarma's growth potential: Evaluate Evrofarma's management, business model, and growth potential.
- Determine Evrofarma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Evrofarma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Evrofarma Stock analysis
When running Evrofarma's price analysis, check to measure Evrofarma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evrofarma is operating at the current time. Most of Evrofarma's value examination focuses on studying past and present price action to predict the probability of Evrofarma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evrofarma's price. Additionally, you may evaluate how the addition of Evrofarma to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |